InvestorsHub Logo
Followers 10
Posts 1244
Boards Moderated 0
Alias Born 10/12/2012

Re: None

Saturday, 01/04/2014 11:07:41 PM

Saturday, January 04, 2014 11:07:41 PM

Post# of 30990
Is it greed that drives the arguements? Interesting post in the Sunday Standard, an India publication. Looks like Big Pharma sees potential in neutraceuticals. Are prescription drugs topping out?

Excerpt:
"The burgeoning interest in nutraceuticals (products extracted from natural sources or manufactured synthetically to supplement the regular diet and help prevent nutrition-related disorders) should come as no surprise.

More than 40 per cent deaths in developing countries are due to nutrition-related disorders, according to the World Health Organization.

Eight of the top 15 risk factors are related to nutrition and contribute nearly 40 per cent of the total deaths and 30 per cent of total disease burden in developing countries, including India.

It’s not just a developing world trend either.

Globally, pharmaceutical companies have begun competing head-to-head for market share and the acquisition of emerging health and wellness products with growth potential, such as Nestlé Health Science’s recent investment in Axona.

And why not? A recent survey of 1,000 vitamin consumers in the US had 93 per cent respondents saying they felt more confident about their health when taking a vitamin or supplement–a jump from 71 per cent customers last year.

Back at home, “the market is being driven by the changing lifestyles of consumers and increased knowledge about nutritional supplements.

It is also due to a shift towards preventive therapies, increase in disposable incomes, increase in healthcare spending and ageing population,” says Dr Shubnum Singh, dean, nursing, Allied Health & Wellness Programs, Max Hospitals Group.

The size of the global nutraceuticals market is pegged at $117 billion."

Article at:
http://www.newindianexpress.com/thesundaystandard/article599312.ece

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.